Core Insights - Staar Surgical's international revenue performance is critical for assessing its financial resilience and growth prospects [1][2][3] Group 1: Financial Performance - The company's total revenue for the quarter was $44.32 million, a decline of 55.2% year over year [4] - Other International contributed $18.18 million, accounting for 41% of total revenue, which was a surprise of -24.34% compared to the consensus estimate of $24.03 million [5] - Japan generated $10.92 million, representing 24.6% of total revenue, with a positive surprise of +8.28% compared to the projected $10.08 million [6] - China accounted for 12% of total revenue, translating to $5.3 million, with a significant surprise of +454.87% against the expected $0.96 million [7] Group 2: Future Revenue Predictions - For the current fiscal quarter, analysts anticipate total revenues of $89.27 million, reflecting a 0.8% increase year over year [8] - Expected revenue contributions for the current quarter are 23.8% from Other International ($21.26 million), 12.8% from Japan ($11.38 million), and 54.2% from China ($48.36 million) [8] - For the full year, total revenue is projected to be $258.21 million, down 17.7% from the previous year, with specific contributions from Other International (36.1%), Japan (17.3%), and China (36.9%) [9] Group 3: Market Context - Staar Surgical's reliance on international markets presents both opportunities and challenges, necessitating close monitoring of international revenue trends [10] - The interconnected global economy and geopolitical factors are increasingly influencing earnings predictions for companies with overseas operations [10][11]

Company Performance - Staar Surgical reported a quarterly loss of $0.07 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.56, representing an earnings surprise of +87.50% [1] - The company posted revenues of $44.32 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 6.63%, although this is a decline from year-ago revenues of $99 million [2] - Over the last four quarters, Staar Surgical has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Movement and Outlook - Staar Surgical shares have increased by approximately 11.2% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] - The future performance of the stock will largely depend on management's commentary during the earnings call and the earnings outlook for the upcoming quarters [3][4] - The current consensus EPS estimate for the next quarter is $0.18 on revenues of $87.83 million, while for the current fiscal year, it is -$0.78 on revenues of $258.21 million [7] Industry Context - The Medical - Dental Supplies industry, to which Staar Surgical belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of Staar Surgical's stock may also be influenced by the overall industry outlook, as empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]

Core Insights - Henry Schein reported quarterly earnings of $1.1 per share, missing the Zacks Consensus Estimate of $1.18 per share, and down from $1.23 per share a year ago, representing an earnings surprise of -6.78% [1] - The company posted revenues of $3.24 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.60%, and up from $3.14 billion year-over-year [2] - The stock has added about 1.2% since the beginning of the year, underperforming the S&P 500's gain of 7.6% [3] Earnings Outlook - The current consensus EPS estimate for the coming quarter is $1.27 on revenues of $3.27 billion, and for the current fiscal year, it is $4.85 on revenues of $12.96 billion [7] - The estimate revisions trend for Henry Schein was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Dental Supplies industry, to which Henry Schein belongs, is currently in the top 24% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% of industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Performance - Staar Surgical reported a quarterly loss of $0.52 per share, which was better than the Zacks Consensus Estimate of a loss of $0.59, and compared to earnings of $0.06 per share a year ago, indicating an earnings surprise of 11.86% [1] - The company posted revenues of $42.59 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.57%, but down from $77.36 million in the same quarter last year [2] - Over the last four quarters, Staar Surgical has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Staar Surgical shares have declined approximately 23.3% since the beginning of the year, while the S&P 500 has decreased by 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.59 on revenues of $41.03 million, and for the current fiscal year, it is -$0.81 on revenues of $260.45 million [7] Industry Outlook - The Medical - Dental Supplies industry, to which Staar Surgical belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - The Cooper Companies, another player in the same industry, is expected to report quarterly earnings of $0.93 per share, reflecting a year-over-year change of +9.4%, with revenues anticipated to be $995.5 million, up 5.6% from the previous year [9][10]